- Home
- WGRX vs NKTX Comparison
WGRX vs NKTX Comparison
Compare WGRX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- NKTX
- Stock Information
- Founded
- WGRX 2022
- NKTX 2015
- Country
- WGRX United States
- NKTX United States
- Employees
- WGRX N/A
- NKTX N/A
- Industry
- WGRX Other Pharmaceuticals
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- NKTX Health Care
- Exchange
- WGRX Nasdaq
- NKTX Nasdaq
- Market Cap
- WGRX 111.0M
- NKTX 123.5M
- IPO Year
- WGRX 2025
- NKTX 2020
- Fundamental
- Price
- WGRX $1.50
- NKTX $1.97
- Analyst Decision
- WGRX
- NKTX Strong Buy
- Analyst Count
- WGRX 0
- NKTX 5
- Target Price
- WGRX N/A
- NKTX $13.50
- AVG Volume (30 Days)
- WGRX 7.3M
- NKTX 539.6K
- Earning Date
- WGRX 11-11-2025
- NKTX 11-06-2025
- Dividend Yield
- WGRX N/A
- NKTX N/A
- EPS Growth
- WGRX N/A
- NKTX N/A
- EPS
- WGRX N/A
- NKTX N/A
- Revenue
- WGRX $36,738,599.00
- NKTX N/A
- Revenue This Year
- WGRX N/A
- NKTX N/A
- Revenue Next Year
- WGRX N/A
- NKTX N/A
- P/E Ratio
- WGRX N/A
- NKTX N/A
- Revenue Growth
- WGRX 82384.51
- NKTX N/A
- 52 Week Low
- WGRX $0.62
- NKTX $1.31
- 52 Week High
- WGRX $7.04
- NKTX $6.49
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- NKTX 41.11
- Support Level
- WGRX N/A
- NKTX $2.00
- Resistance Level
- WGRX N/A
- NKTX $2.08
- Average True Range (ATR)
- WGRX 0.00
- NKTX 0.11
- MACD
- WGRX 0.00
- NKTX -0.03
- Stochastic Oscillator
- WGRX 0.00
- NKTX 2.35
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.